100% Quality Guarantee
PhD-Level Technical Support
Galiximab Antibody - SDS-PAGE
Key Features

Galiximab Antibody (GXBS00161)

SKU GXBS00161
Product Type Research Grade Biosimilar
Antibody Type Monoclonal
Host Species Chimeric
Reactivity Human
Applications ELISA, FACS, Functional assay, Research in vivo
Isotype IgG1-lambda
$409 - $1,138

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

Galiximab Antibody

Galiximab Antibody is a research-grade biosimilar monoclonal antibody targeting CD80. It is a chimeric IgG1-lambda antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.

T-lymphocyte activation antigen CD80 (B7-1) is a ~33 kDa protein. Costimulatory molecule that belongs to the immunoglobulin superfamily that plays an important role in T-lymphocyte activation. Acts as the primary auxiliary signal augmenting the MHC/TCR signal in naive T-cells by acting as a ligand for the CD28 receptor which is constitutively expressed on the cell surface of T-cells. In turn, activates different signaling pathways such as NF-kappa-B or MAPK leading to the production of different cytokines. Also acts as an inhibitor of T-cell activation by acting as a ligand for CTLA4, a decoy receptor, thereby blocking CD28-mediated T-cell priming. In addition, CD28/CD80 costimulatory signal stimulates glucose metabolism and ATP synthesis of T-cells by activating the PI3K/Akt signaling pathway.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose